Vaccinbyrå opens the 1st regional office in Sweden
The International Vaccine Institute (IVI) announced that it has signed a memorandum of understanding with the Swedish Ministry of Foreign Affairs to establish its regional office in Stockholm.
With the opening of the new office, IVI aims to create an international hub for global health research, innovation and collaboration in Sweden’s capital.
The Swedish office also marks the institute’s first regional point of sale next to the head office in Korea. Based on the permanent partnership with the Swedish government and Karolinska Institutet (KI), the European Office will conduct collaborative projects with regional member states and various public and private partners, especially independent vaccine R&D projects.
“We are pleased to announce the establishment of IVI’s regional office in Stockholm. IVI looks forward to deepening its historic partnership with the Swedish government, KI and other stakeholders to build another international website for global health research and innovation, which promotes IVI’s vision of a world free of infectious diseases that can be prevented with vaccines, ” IVI’s chairman of the board said George Bickerstaff.
Sweden’s Minister for International Development Cooperation Matilda Ernkrans also said, “It is good news that IVI has shown determination to continue to discover, develop and deliver safe, effective and affordable vaccines for global public health and that IVI will establish an office in Europe. its reach, deepen its commitment on the continent and improve its work in Africa as part of this platform. “
Ernkrans expressed enthusiasm that IVI chose Stockholm as the site for its regional office as Sweden has been a member and supporter of IVI for two decades through annual contributions to IVI and active role in its Board of Trustees witnessed the successful contributions from IVI’s work.
“The Swedish government has been a key supporter of IVI since its inception, and has provided core and project funding through the Swedish International Cooperation Agency (Sida) to accelerate vaccine research on public health and promote global goals.” IVI’s Director General Jerome Kim said.
From helping to develop the world’s first affordable oral cholera vaccine to strengthening Covid-19 low-resource monitoring efforts, Sweden’s support has enabled IVI’s work across the vaccine and the global health spectrum, and IVI is pleased to enter the next phase of our partnership, Kim added.
Sweden was one of the first countries to sign the IVI Establishment Agreement in 1997 and began financing IVI in 2002 through Sida.
Since IVI’s first research collaboration with the University of Gothenburg and Swedish Biological Laboratories in 2000, Sweden has played an important role in the development of IVI’s landmark oral cholera vaccine (OCV), Shanchol, and later, Euvichol and Euvichol Plus, vaccines developed through technology transfer from IVI and pre-qualified by the WHO, according to IVI.
IVI has delivered over 56 million doses of these low-cost OCVs worldwide through its global warehouse.
Sida also continues to support a range of epidemiology and vaccine programs for the control of cholera, typhoid and covid-19, including generating evidence of disease burden in resource-efficient environments in Asia and Africa, accelerating the development and introduction of oral cholera and typhoid at affordable conjugate vaccines and help increase the capacity of developing countries to implement immunization programs effectively.